Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

By N. Doria-Rose, M. Suthar, M. Makowski, S. O'connell, A. McDermott, B. Flach, J. Ledgerwood, J. Mascola, Barney S. Graham, Bob C. Lin and 20 more. New England Journal of Medicine, 2021

631 citations recorded by the source corpus.

* Interim results from a phase 3 trial of the Moderna mRNA-1273 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine indicated 94% efficacy in preventing coronavirus disease 2019 (Covid-19). 1 The durability of protection is currently unknown. We describe mRNA1273-elicited binding and neutralizing antibodies in 33 healthy adult

Subfields: Animal Science and Zoology, Infectious Diseases, Surgery

View Paper: https://www.semanticscholar.org/paper/92fd49f47306d8513ad1813d6367d199947da3f2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. W. Garcia-Beltran
2. Evan C. Lam
3. Kerri J. St. Denis
4. Adam D Nitido
5. B. Hauser
6. J. Feldman
7. D. Gregory
8. M. Poznansky

Citations in the corpus

• mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant (2021, background): “Several reports have measured the decay of neutralizing antibody responses raised by mRNA COVID-19 vaccines with a half-life of 69-173 days (Doria-Rose et al., 2021; Levin et al., 2021).”